Drug General Information (ID: DDI6LYN75W)
Drug Name			Linezolid		Drug Info		Yohimbine		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antibiotics				Mydriatics
Structure

Mechanism of Linezolid-Yohimbine Interaction (Severity Level: Moderate)
Additive hypertensive effects Click to Show/Hide Mechanism Graph
Drug Name		Linezolid				Yohimbine
Mechanism 1		Hypertensive effects				Hypertensive effects
Key Mechanism Factor 1
		Factor Name		Hypertensive effects
		Factor Description		Hypertension is defined as a blood pressure reading above a prescribed limit (130/90 mmHg). Most people with hypertension have no signs or symptoms; others may experience: severe headache, shortness of breath, nosebleeds, severe anxiety, and feeling a tingling sensation in the neck or head.
Mechanism Description		Additive hypertensive effects by the combination of Linezolid and Yohimbine
Increased risk of hyperpyrexia Click to Show/Hide Mechanism Graph
Drug Name		Linezolid				Yohimbine
Mechanism 2		Hyperpyrexia				Hyperpyrexia
Key Mechanism Factor 2
		Factor Name		Hyperpyrexia
		Factor Description		Hyperthermia is an extreme, life-threatening increase in core body temperature. If hyperthermia persists for a long time or worsens, more serious symptoms may occur, such as confusion, headache, constricted pupils, vomiting, diarrhea, and decreased urine output.
Mechanism Description		Increased risk of hyperpyrexia by the combination of Linezolid and Yohimbine

Recommended Action
Management		While clinical data are lacking, yohimbine should preferably not be used with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with yohimbine.

References
1	Fugh-Berman A "Herb-drug interactions." Lancet 355 (2000): 134-8. [PMID: 10675182]
2	Product Information. Matulane (procarbazine). Roche Laboratories, Nutley, NJ.
3	Product Information. Zyvox (linezolid) Pharmacia and Upjohn, Kalamazoo, MI.